AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
The current AbbVie(ABBV) stock price is $287.61, with a market capitalization of 506.16B. The stock trades at a price-to-earnings (P/E) ratio of 80.97 and offers a dividend yield of 2.38%.
On 2026-10-28, AbbVie(ABBV) stock traded between a low of $281.23 and a high of $288.80. Shares are currently priced at $287.61, which is +2.3% above the low and -0.4% below the high.
AbbVie(ABBV) shares are trading with a volume of 3.11M, against a daily average of 5.14M.
During the past year, AbbVie(ABBV) stock moved between $190.75 at its lowest and $291.40 at its peak.
During the past year, AbbVie(ABBV) stock moved between $190.75 at its lowest and $291.40 at its peak.
ABBV News
AbbVie (NYSE: ABBV) has submitted a Biologics License Application to the U.S. FDA for etentamig in relapsed or refractory multiple myeloma. The filing is backe...
ETF Why JEPI’s Total Return Has Outpaced Its Payout JEPI's share price keeps climbing while its monthly cash payments quietly shrink, and the reason behind that...
Investing Retire on Dividends: 5 High-Yield Stocks Boomers Are Buying and Holding Forever Treasury yields near 5% make dividend stocks work harder to justify th...
Analyst ratings
75%
of 32 ratingsMore ABBV News
Chicago, IL – October 28, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the l...
AbbVie (ABBV Quick QuoteABBV - Free Report) is set to report third-quarter 2026 earnings on Oct. 30, before the opening bell. The Zacks Consensus Estimate...
AbbVie has delivered a powerful run over the past few years, so the obvious question now is whether today's US$285.64 price still lines up with the cash the bus...
AbbVie (ABBV) announced the U.S. Food and Drug Administration has approved a subcutaneous induction regimen for Skyrizi for adults with moderately to severely a...
Investing Forget Chasing 7% Yields: These 5 Dividend Stocks Offer Something Different Treasury yields have turned dividend investing into a minefield, but five...
As previously reported, Guggenheim analyst Yatin Suneja downgraded Avalo Therapeutics (AVTX) to Neutral from Buy and removed the firm’s prior price target after...
Goldman Sachs raised the firm’s price target on AbbVie (ABBV) to $294 from $258 and keeps a Neutral rating on the shares. AbbVies lutikizumab met Phase 3 endpoi...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.